Human Data Can’t Wait for Clinical Trials.
3D HUMAN BIOLOGY-ON-A-CHIP FOR HUMANIZED DRUG DISCOVERY AND CLINICAL DECISION MAKING
Accelerating drug discovery with AIM Biotech’s humanized BioAvatar products & services.
From the most demanding basic research, to predictive screens for drug discovery, to the tailored selection of precision medicines, AIM Biotech enables and accelerates the development of cutting-edge therapeutics. This is made possible through AIM Biotech’s BioAvatar technology, which embodies our core expertise in the design and manufacture of sophisticated microfluidic systems and human tissue models. Our BioAvatars combine unmatched recapitulation of human biology with unparalleled ease-of-use, resulting in a powerful solution to move medicine forward.
Humanized pre-clinical insights for increased predictability of clinical outcomes
Acceleration of the drug discovery process through easy-to-implement humanized organ-on-a-chip models
Replacement of animal models in pre-clinical trials
Introducing the idenTx platform
The humanized 3D tissue culture platform for drug discovery
Easy-to-use. Flexible. Scalable. AIM Biotech’s idenTx line of 3D tissue culture chips and plates enable predictive human BioAvatars that recapitulate human microphysiology more accurately than traditional cell culture or animal models. Available in formats for 3, 9, and 40 parallel experiments, idenTx multiplies your throughput in alignment with your drug discovery programs.
All with no special equipment and in conjunction with your existing laboratory workflow and automation. With the new idenTx platform, AIM Biotech has taken our proven AIM chips and plates to the next level of scalability and refinement, enabling human-focused, clinically-relevant results that accelerate the development of cutting-edge therapies.
Human biology-on-a-chip. Simplified.
idenTx 3 Chip
AIM Biotech’s proven 3D Cell Culture Chip, DAX-1
This is AIM Biotech’s proven 3D Cell Culture Chip, now part of the idenTx family. Designed in a microscope slide format, this most basic component of the idenTx family enables 3 simultaneous experiments. It is ideal for establishing experimental feasibility or for general low-throughput applications.
Human biology-on-a-chip. Standardized.
idenTx 9 Plate
Three fully-integrated idenTx 3 Chips enable 9 simultaneous experiments; scale up for introduction of plate-based robotics and automation.
Human biology-on-a-chip. Multiplied.
idenTx 40 Plate
Highest throughput plate option, enabling 40 simultaneous experiments to fully accelerate drug discovery through high-content screening.
Human Data. Experimental Simplicity.
Scalability without Compromise.
Unmatched ease-of-use: no special handling, no special training, no special hardware
Built in Scalability to take your research from feasibility to higher throughput screening
Your study. Our lab. Human data.
Contract research services for humanized, organ-on-a-chip studies
With AIM Biotech contract research services, increasing throughput while maintaining assay sophistication is our expertise. Our pharma-focused solutions combine speed and simplicity with the ability to model complex tissues that you expect from organ-on-a-chip assays.
Let AIM Biotech accelerate your drug discovery programs using our humanized BioAvatar Technology in our state-of-the-art research services lab. Our team can even work with you to design, develop, and execute custom assays to deliver human-focused, clinically-relevant results that move your drug discovery programs forward.
Custom assay development
Rapid humanized throughput
Functional immuno-oncology assays
Answer primary research questions
Data on routine screens
In-vitro organ models
Your path to predictive data and insightful diagnostics.
Simple-to-use, fully scalable microfluidic systems in plate and chip formats to recapitulate human physiology.
Validated protocols in T-cell efficiency, immunotherapies, cell migration, vasculogenesis and more
Custom assay development and higher-throughput, high-content screening with assays of your choice
Mechanism of action
In vitro screening
ADME toxicity studies
Leveraging AIM’s BioAvatar technology to tackle previously-unknown effects of immune protein ligands in tumors
Although immune checkpoint protein PD-1 activation is known to participate in tumor development and to inhibit adoptive T cell therapy effects, the expression of its ligand PD-L1 during...
New application note with AIM Biotech and Nikon: Evaluating CAR-T cell dynamics in a 3D tumor microenvironment using confocal imaging
AIM Biotech and Nikon Instruments have produced a new application note demonstrating one way to more easily study the immune effects of Chimeric Antigen Receptor T (CAR-T) by combining AIM's...
Simplify and isolate: A case study on how idenTx streamlines preclinical research
For today’s post in our immune checkpoint series, we’ll discuss work published in Cell in 2018 by Sade-Feldman et al., and how they leveraged the economy of cost from AIM’s idenTx organ-on-a-chip...